Neurosyphilis: Symptoms, Dangers, and Treatment

What is Neurosyphilis?

Neurosyphilis is a serious infectious complication of syphilis, a sexually transmitted infection (STI). It develops when the causative bacterium, Treponema pallidum, invades the central nervous system (CNS). The infection can affect:

• The meninges (the protective membranes surrounding the brain and spinal cord)
• The brain itself (cerebral parenchyma)
• The spinal cord
• The blood vessels supplying the CNS

Neurosyphilis is not a single, uniform condition. Instead, it includes a spectrum of clinical forms, ranging from entirely asymptomatic to profoundly disabling.

Timeline of Presentation

• Early manifestations (meningeal and meningovascular forms): typically appear months to a few years after initial infection.
• Late manifestations (general paresis, tabes dorsalis) may develop 10 to 30 years after the primary infection. These symptoms can appear earlier in immunocompromised individuals, particularly those with HIV/AIDS.

Key early warning signs may include:

• Cranial nerve dysfunction
• Meningitis
• Meningovascular involvement
• Stroke and altered mental status

Treatment and Prognosis

Neurosyphilis is treated with antibiotics, primarily intravenous penicillin G. Alternatively, ceftriaxone may be used. Prognosis varies considerably depending on:

• The clinical form of neurosyphilis
• The timeliness of diagnosis and treatment

Outcomes range from complete recovery (in early, promptly treated cases) to permanent neurological disability if treatment is delayed or the disease is advanced.

---

Causes

Neurosyphilis is caused by the spirochete bacterium Treponema pallidum, which is famously described as the “great imitator” because it can mimic a vast array of other medical conditions through its diverse symptom spectrum.

How Does Syphilis Progress to Neurosyphilis?

Syphilis typically progresses through four stages if left untreated: primary, secondary, latent, and tertiary. Neurosyphilis, however, is distinct: it can develop at any point after infection, not exclusively in the tertiary stage. In other words, it does not require prior passage through all stages to occur.

Current evidence suggests that Treponema pallidum invades the cerebrospinal fluid (CSF) in the majority of patients shortly after infection. In most cases, the immune system resolves this CNS invasion spontaneously without producing symptoms or permanent damage. However, in a minority of patients, the infection persists and triggers an inflammatory response in the CNS. It is these individuals who develop clinically recognizable neurosyphilis.

Historical Context and Modern Epidemiology

Before penicillin became available, neurosyphilis was alarmingly widespread. It affected an estimated 25–35% of all syphilis patients. The antibiotic era dramatically reduced its incidence. However, since the late 20th century, global syphilis rates have been rising again, driven in part by declining condom use, increasing numbers of sexual partners, and reduced public health vigilance.

Today, neurosyphilis is fortunately much rarer than in the pre-antibiotic era. It is most commonly encountered in immunocompromised patients, particularly individuals with HIV infection who have low CD4+ lymphocyte counts and limited access to antiretroviral therapy. In this population, impaired cellular immunity allows T. pallidum to establish and sustain CNS infection more readily.

The Five Clinical Forms

Five distinct forms of neurosyphilis are recognized, spanning from early to late presentations:

1. Asymptomatic neurosyphilis
2. Meningeal syphilis
3. Meningovascular syphilis
4. General paresis (parenchymatous neurosyphilis)
5. Tabes dorsalis

Each is described in detail in the following section.

---

Symptoms

1. Asymptomatic Neurosyphilis

As the name suggests, this form produces no clinical symptoms. Affected patients are entirely unaware of CNS involvement. The diagnosis is established incidentally through the detection of characteristic CSF abnormalities (elevated white cell count, elevated protein, positive CSF syphilis serology) in a patient already known to have syphilis based on blood tests.

Although asymptomatic, this form is clinically significant because it can progress to symptomatic neurosyphilis if untreated, and it is the form that most strongly justifies the need for CSF examination in syphilis patients with risk factors for CNS involvement.

2. Meningeal Syphilis

Meningeal syphilis occurs when the meninges, which are the three-layered protective membrane surrounding the brain and spinal cord, become inflamed. This condition can appear anywhere from a few weeks to several years after the initial syphilis infection. It is the most common early symptomatic form of neurosyphilis.

Clinical features closely resemble those of bacterial or viral meningitis and include:

• Headache: often severe and persistent
• Neck stiffness (meningism)
• Nausea and vomiting
• Less commonly: seizures, photophobia, vision loss, or hearing loss
• Cranial nerve palsies: particularly affecting cranial nerves II (optic), III (oculomotor), VI (abducens), VII (facial), and VIII (vestibulocochlear)

Important clinical note: The combination of meningeal symptoms with cranial nerve involvement should always prompt consideration of syphilis as a cause, particularly in sexually active individuals and those with HIV.

3. Meningovascular Syphilis

Meningovascular syphilis shares the meningeal inflammatory features described above. However, it also involves inflammatory arteritis, which is vasculitis of the cerebral blood vessels and sometimes those of the spinal cord. This introduces the significant risk of ischemic stroke.

This form may develop anywhere from a few months to several years after infection and is characterized by:

• All features of meningeal syphilis (headache, neck stiffness, cranial nerve palsies).
• Stroke or transient ischemic attack (TIA): This often occurs in a relatively young patient without traditional cardiovascular risk factors. Such a presentation should raise suspicion for an infectious or inflammatory vasculopathy.
• Prodromal symptoms preceding stroke: weeks to months of personality changes, mood disturbance, headaches, or insomnia.

When spinal cord vessels are involved (spinal meningovascular syphilis), patients may develop:

• Muscle weakness, particularly in the lower limbs.
• Sensory loss below the level of cord involvement
• Muscle atrophy
• Bladder and bowel dysfunction

4. General Paresis (Parenchymatous Neurosyphilis)

General paresis, also called dementia paralytica or general paralysis of the insane (a historically used but now outdated term), represents a late manifestation of neurosyphilis. It typically develops 3 to 30 years after the initial infection. It results from chronic meningoencephalitis (diffuse inflammation and subsequent degeneration of the brain parenchyma itself), leading to progressive cerebral atrophy.

Symptoms are divided into early and late phases, and can develop either gradually and insidiously or with a relatively abrupt onset:

Early Symptoms

• Irritability and emotional lability
• Personality changes: disinhibition, social inappropriateness, loss of social judgment
• Sleep disturbances
• Memory lapses: initially subtle forgetfulness progressing to significant amnesia
• Concentration difficulties

Late Symptoms

• Severe memory impairment and dementia.
• Impaired judgment and insight.
• Pupillary abnormalities: The Argyll Robertson pupil is a classic finding. The pupil accommodates, meaning it constricts for near vision, but it does not react to direct light (“accommodates but does not react”).
• Tremors: initially fine tremors of the hands, face, and tongue; may become coarser.
• Dysarthria (slurred, hesitant speech).
• Mental confusion and disorientation.
• Delusions (often grandiose) and hallucinations.
• Seizures.
• Psychiatric syndromes: including depression, delirium, mania, and psychosis.

Diagnostic importance: General paresis must be considered in the differential diagnosis of any patient presenting with unexplained progressive dementia, personality change, or new-onset psychiatric illness, particularly if there are historical risk factors for syphilis exposure.

5. Tabes Dorsalis

Tabes dorsalis is the most delayed manifestation of neurosyphilis, typically developing 5 to 50 years after the initial syphilis infection. It results from the slow, progressive degeneration of the posterior columns, also known as the dorsal funiculi, of the spinal cord and the posterior nerve roots. These pathways are responsible for proprioception (the sense of body position), vibration, light touch, and coordination.

The precise mechanism by which T. pallidum causes this selective posterior column degeneration remains incompletely understood.

Clinical features include:

• Lightning (lancinating) pains: sudden, brief, and excruciating stab-like pains affecting the legs or abdomen. These are among the most characteristic and distressing symptoms
• Sensory ataxia: incoordination resulting from loss of proprioceptive feedback; patients walk with a characteristic wide-based, stamping gait and tend to look at the ground to compensate for the loss of positional sense
• Positive Romberg sign: inability to maintain balance when standing with feet together and eyes closed (reliance on vision to compensate for proprioceptive loss)
• Loss of deep tendon reflexes (areflexia), particularly at the knees and ankles
• Loss of vibration sense and joint position sense
• Bladder dysfunction: overflow incontinence due to loss of bladder sensation and impaired detrusor function
• Vision loss: via optic atrophy
• Argyll Robertson pupils (as described in general paresis)
• Charcot joints (neuropathic arthropathy): painless, destructive arthritis of weight-bearing joints (knees, hips, ankles), resulting from the loss of protective pain and proprioceptive sensation

---

Other Complications of Syphilis

The following two complications, which involve vision and hearing, are distinct from neurosyphilis itself. However, they may still occur alongside it. Both can represent the initial presenting manifestation of syphilis and should prompt screening in at-risk individuals.

Ocular Syphilis

Ocular syphilis can occur at any stage of the disease and involves virtually any structure of the eye. It represents a recognized and increasing public health concern, with case reports rising alongside global syphilis incidence.

Clinical manifestations include:

• Uveitis: both anterior and posterior, and panuveitis (the most common presentation overall)
• Optic neuropathy (optic neuritis or retrobulbar neuritis)
• Retinal vasculitis
• Interstitial keratitis
• Iridocyclitis

Visual symptoms include blurred vision, floaters, photophobia, and, in severe or untreated cases, permanent visual impairment or blindness.

Clinical alert: Ocular syphilis may be the first sign of syphilis in an otherwise unsuspected patient. Any individual presenting with new-onset uveitis or unexplained visual changes should be screened for syphilis, particularly if sexual risk factors are present. Ocular syphilis is treated as neurosyphilis (intravenous penicillin regimen).

Otosyphilis

Otosyphilis refers to syphilitic involvement of the cochleovestibular system, which includes the inner ear structures responsible for hearing and balance. It typically presents with:

• Sensorineural hearing loss (SNHL): may be unilateral or bilateral, and can onset suddenly (resembling sudden sensorineural hearing loss from other causes) or progress gradually
• Tinnitus: ringing, buzzing, or hissing in the affected ear(s)
• Vertigo and balance disturbance

In severe or untreated cases, otosyphilis can result in permanent bilateral deafness.

Clinical alert: Like ocular syphilis, otosyphilis may be the presenting manifestation of syphilis. Syphilis serology should be included in the workup of any patient with new-onset sensorineural hearing loss, tinnitus, or vertigo. This is particularly important in younger adults when no other identifiable cause is present. Treatment follows the neurosyphilis antibiotic regimen.

---

Diagnosis

The diagnosis of neurosyphilis is complex and cannot be established by any single laboratory test. It requires the integration of clinical assessment, blood serology, and CSF analysis.

Blood Serology

All patients suspected of neurosyphilis require serological testing for syphilis:

• Non-treponemal tests (screening): These include the Venereal Disease Research Laboratory (VDRL) and Rapid Plasma Reagin (RPR) tests. They are quantitative and reflect disease activity, so they can also be used to monitor treatment response.
• Treponemal tests (confirmatory): T. pallidum particle agglutination assay (TPPA) and fluorescent treponemal antibody absorption (FTA-ABS) remain positive for life, even after successful treatment.

CSF Examination (Lumbar Puncture)

Analysis of cerebrospinal fluid (CSF) obtained by lumbar puncture is the cornerstone of neurosyphilis diagnosis. It is indicated in patients with:

• Neurological or psychiatric symptoms with known or suspected syphilis
• Ocular or auditory symptoms with known syphilis
• Serological evidence of syphilis with HIV co-infection
• Treatment failure or relapse

Characteristic CSF findings in neurosyphilis include:

• Elevated white blood cell count (pleocytosis): typically lymphocytic, >5 cells/mm³
• Elevated protein concentration
• Positive CSF VDRL (the most specific test for neurosyphilis, but it has low sensitivity. A negative result does not exclude the diagnosis)
• Elevated CSF FTA-ABS (high sensitivity but lower specificity)

Critical caveat: Patients with primary or secondary syphilis often exhibit mild CSF abnormalities. However, this does not automatically indicate neurosyphilis if neurological symptoms are absent. Conversely, a completely normal CSF effectively excludes neurosyphilis in most clinical scenarios.

Neuroimaging

• MRI of the brain (with gadolinium contrast): Can reveal meningeal enhancement, cerebral infarctions (in meningovascular syphilis), cortical atrophy (in general paresis), or white matter changes. MRI is most useful to assess the extent of CNS involvement and to exclude other causes.
• CT scan: Less sensitive than MRI for parenchymal changes but useful in acute settings.

Neurological and Ophthalmological Evaluation

• Complete neurological examination: Including cranial nerve function, motor and sensory testing, reflexes, coordination (Romberg test, tandem gait), and cognitive assessment
• Fundoscopy and slit-lamp examination: To detect signs of ocular syphilis (uveitis, optic disc swelling, retinal vasculitis)
• Audiological testing: Pure-tone audiometry in patients with suspected otosyphilis
• Neuropsychological testing: May be indicated in patients with cognitive or behavioral symptoms

---

Treatment

Urgency of Treatment

Untreated neurosyphilis can lead to devastating, irreversible neurological damage, such as permanent paralysis, dementia, blindness, deafness, and even death. Treatment should therefore be initiated immediately upon diagnosis. The principle is clear: the earlier treatment begins, the greater the chance of full recovery. This is because the damage caused by untreated infection accumulates over time, and much of it is irreversible.

Hospitalization

Patients diagnosed with neurosyphilis should be hospitalized for initiation of intravenous antibiotic therapy and clinical monitoring.

First-Line Antibiotic Regimens

Two antibiotic regimens are currently recommended for neurosyphilis:

1. Aqueous Crystalline Penicillin G (First Choice)

• Dosage: 18–24 million units per day, administered as 3–4 million units every 4 hours by intravenous infusion (or as a continuous infusion)
• Duration: 10 to 14 days
• Penicillin G achieves treponemicidal concentrations in the CSF and remains the gold standard for neurosyphilis treatment

2. Ceftriaxone (Alternative)

• Dosage: 2 g per day administered by intravenous or intramuscular injection, once daily
• Duration: 10 to 14 days
• Used in patients with penicillin allergy or in settings where IV penicillin is unavailable. Note: patients with true penicillin allergy (confirmed by allergy testing) should ideally be desensitized to penicillin and treated with the first-line regimen, as ceftriaxone data for neurosyphilis are less robust

Penicillin Allergy and Desensitization

• For patients with documented severe penicillin allergy, referral to an allergy specialist for skin testing and desensitization is the recommended approach. This is especially important because penicillin is superior in this indication.
• Doxycycline is not a reliable alternative for neurosyphilis due to poor CSF penetration.

Treatment Outcomes by Clinical Form

Prognosis after treatment varies significantly by disease stage:

Post-Treatment Follow-Up

Long-term follow-up is essential to confirm treatment success and detect relapse:

• Repeat CSF examination: at 6 and 12 months after treatment (and at 24 months in HIV-positive patients). The goal is to check for normalization of CSF cell count, protein, and VDRL titer.
• Blood RPR/VDRL monitoring: quantitative titers should fall by at least fourfold within 12–24 months; failure to decline suggests treatment failure or reinfection.
• Clinical neurological reassessment: at each follow-up visit to document symptom evolution
• Treatment failure: defined by persistent or increasing CSF pleocytosis, failure of CSF VDRL to decline, or clinical deterioration, warrants repeat treatment and specialist consultation.

Management of Concurrent Conditions

• HIV co-infection: All patients with neurosyphilis should be tested for HIV. In HIV-positive patients, initiation or optimization of antiretroviral therapy (ART) alongside neurosyphilis treatment improves outcomes
• Partner notification: All sexual partners within the relevant exposure period should be traced, notified, and evaluated for syphilis
• Repeat screening: Patients treated for neurosyphilis should be offered screening for other STIs including HIV, gonorrhea, chlamydia, and hepatitis B/C

---

Sources and Bibliography

• National Institute of Neurological Disorders and Stroke (NINDS), NIH. Neurosyphilis.
• Centers for Disease Control and Prevention (CDC). Neurosyphilis, Ocular Syphilis, and Otosyphilis.
• Ha T, Tadi P, Dubensky L. Neurosyphilis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from PubMed
• Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187. CDC MMWR
• Marra CM. Neurosyphilis. Continuum (Minneapolis, Minn.). 2015;21(6 Neuroinfectious Disease):1714–1728. DOI: 10.1212/CON.0000000000000250
• Ropper AH. Neurosyphilis. New England Journal of Medicine. 2019;381(14):1358–1363. DOI: 10.1056/NEJMra1906228
• Ghanem KG. REVIEW: Neurosyphilis: a historical perspective and review. CNS Neuroscience & Therapeutics. 2010;16(5):e157–168.
• Bhatti MT, Bhatti AB, Meltzer E. Ocular syphilis: an update. Current Infectious Disease Reports. 2020;22(3):12.
• European Centre for Disease Prevention and Control (ECDC). Syphilis: Annual Epidemiological Report.